Genentech, Novartis re-up chronic hive campaign with celebrity comedian spokesperson – Endpoints News

While chronic hives are no laughing matter, Genentech and Novartis are partnering with a well-known comedian to raise awareness of the condition.
Vicki Lawrence, known for her work as a cast member on “The Carol Burnett Show,” is also a patient. She was diagnosed with chronic idiopathic urticaria (CIU), also known as chronic spontaneous urticaria (CSU), after suffering with relentless itching in her hands that eventually spread.
Unlock this story instantly and join 149,900+ biopharma pros reading Endpoints daily — and it’s free.
Teva on Wednesday fired back at GSK after the UK-based drugmaker sought to squash Teva’s attempt to get its “skinny” label case overturned by the US Supreme Court.
Teva filed a reply to GSK on Wednesday, slamming the firm’s claims around these label carve-outs, which generic drugmakers use frequently to get competition on the market before all the patented indications of the reference product can be challenged.
Pharma’s big swing to digital advertising is finally losing steam — but still growing at a double-digit pace. While the massive spending increases in 2020 (28%) and 2021 (26%) are now in the pandemic-pushed rearview mirror, eMarketer is still forecasting strong double-digit growth for the industry over the next three years.
Its latest healthcare and pharma digital advertising report predict $15.8 billion in spending this year, a 14% increase year over year, and additional increases of 12.3% and 10.5% for 2023 and 2024, respectively. The forecasted result would land the industry just shy of $20 billion ($19.66B) in annual spending by 2024.
Unlock this story instantly and join 149,900+ biopharma pros reading Endpoints daily — and it’s free.
It is no secret that Merck KGaA has been on an expansion drive across the US and Ireland over the past year, but its latest move will look to boost the company’s presence in mainland Europe too.
The company is looking to invest around €130 million ($129 million) into single-use assemblies as part of the production of Covid-19 vaccines and other therapeutics at its site in Molsheim, France, a city in the east of the country. The investment in the 50-year-old site will also aim to create around 800 jobs by 2028.
Pharma companies have condemned a federal judge’s ruling that a Texas business shouldn’t be required to cover HIV-prevention drugs under religious freedom law.
Braidwood Management, Kelley Orthodontics and a handful of Texas residents filed a complaint against the US back in 2020, arguing that an Affordable Care Act (ACA) mandate requiring the coverage of preventative services, including pre-exposure prophylaxis (PrEP) HIV drugs, violates their religious beliefs. US district judge Reed O’Connor sided with plaintiffs on Wednesday, writing in his opinion that the mandate infringes on Braidwood’s rights under the Religious Freedom Restoration Act.
Unlock this story instantly and join 149,900+ biopharma pros reading Endpoints daily — and it’s free.
Alnylam has detailed positive APOLLO-B data for its pivotal trial of patisiran in treating transthyretin-mediated — or ATTR — amyloidosis with cardiomyopathy. And the results spell out a clear advantage over a placebo in preventing a rapid decline in a 6-minute walk test.
But bound to get immediate attention are unanswered questions on the drug’s health benefits and how the drug and placebo data tracked in the study for an increasingly common heart ailment compared to the disaster that befell a rival therapy at BridgeBio. On that score, there was a wild difference between the two studies in the placebo arm, where patients typically see swift deterioration.
Unlock this story instantly and join 149,900+ biopharma pros reading Endpoints daily — and it’s free.
Revance Therapeutics announced Thursday that its first FDA approval has finally arrived for its Botox competitor, known as Daxxify, after initially submitting its original BLA way back in January 2020.
The botulinum toxin products will compete to temporarily improve moderate to severe frown lines, and for what Revance estimates is a $3.2 billion and growing market.
Revance is looking to corner a slice of that market with its longer-lasting, potentially twice-yearly injection, whereas those using Botox may have to return for more injections every three to four months. Wall Street biotech analysts previously indicated that this difference may be key for Revance in doing better than other previously launched Botox knock-offs.
Neulasta, one of Amgen’s oldest drug franchises, has another biosimilar to contend with.
German pharma Fresenius Kabi announced on Tuesday that the FDA has approved its pegfilgrastim biosimilar, to be marketed as Stimufend. The drug will add to a growing arsenal of biosimilars used to treat neutropenia, a condition common among chemotherapy patients where neutrophils, a type of white blood cell, are too low.
Illumina on Tuesday laid out two scenarios for its $8 billion Grail acquisition, both of which put itself in a tough spot.
The San Diego-based company plans to appeal a European Commission decision to block the merger, with the bloc reasoning Illumina could use its DNA sequencing dominance to throttle Grail competitors’ access to the technology. But if the lengthy appeal fails, Illumina is preparing for another option: divesting Grail.
Unlock this story instantly and join 149,900+ biopharma pros reading Endpoints daily — and it’s free.
Giuseppe Ciaramella joined Moderna in 2014, back when the mRNA specialist only employed about 70 people. There, as CSO of the infectious disease division, he helped build the initial mRNA vaccine pipeline and steered Moderna’s first vaccine program toward an IND.
He left for Beam Therapeutics four years later, before a wildly successful Covid-19 vaccine propelled Moderna to the biotech hall of fame.
Unlock this story instantly and join 149,900+ biopharma pros reading Endpoints daily — and it’s free.
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas
© Endpoints Company 2022
If you’re already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We’ll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS NEWS Daily at 11:30 AM ET
EARLY EDITION Daily at 7:15 AM ET
ENDPOINTS PHARMA Daily at 2 PM ET
ENDPOINTS MARKETING RX Tue at 2 PM ET
ENDPOINTS FDA+ Wed at 2 PM ET
ENDPOINTS MANUFACTURING Thu at 2 PM ET
ENDPOINTS WEEKLY Sat at 6 AM ET

source

CATEGORIES
Share This

COMMENTS

Wordpress (0)
Disqus ( )